studyName: DHART SPORE Project 3 Phase 2 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) dataStatus: Data Pending initiative: Developmental and HyperActive Ras Tumor Specialized Programs of Research Excellence studyLeads: Kevin Shannon Mignon Loh studyStatus: Active diseaseFocus: Neurofibromatosis type 1 institutions: University of California, San Francisco fundingAgency: NIH-NCI manifestation: JMML relatedStudies: syn51133957 syn51298831 syn51133914 syn51133924 studyFileviewId: syn51133961 syn51133958 syn51133959 syn51133961 syn51133960
Drop files to upload
DHART SPORE Project 3 Phase 2 - A High Content Clinical Trial of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML) page is loading…